Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4353)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 24, 2025 (publication date) through May 20, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. World J Clin Oncol 2025; 16(3): 101766 [PMID: 40130059 DOI: 10.5306/wjco.v16.i3.101766] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. World J Clin Oncol 2025; 16(3): 101766 [PMID: 40130059 DOI: 10.5306/wjco.v16.i3.101766] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v16/i3/101766.htm |
| Number | Citing Articles |
| 1 |
Mikako Tsuruta, Yasuhiro Nakashima, Kei Aoyagi, Ryusaku Hosoya, Takahiro Ando, Atsushi Nakagawa, Midori Wakiya, Chika Noguchi. Successful Osimertinib Rechallenge Under Systemic Corticosteroid Administration in EGFR T790M-positive Lung Adenocarcinoma After Osimertinib-induced Interstitial Lung Disease. Haigan 2026; 66(2): 60 doi: 10.2482/haigan.66.60
|
| 2 |
Yong-liang Niu, Ying Yang, Jing-feng Shi, Ming-feng Han, Di-ming Wang. Case Report: Furmonertinib-induced acute interstitial lung disease. Frontiers in Pharmacology 2026; 16 doi: 10.3389/fphar.2025.1742670
|
| 3 |
Jia-feng Wang, Lei-lei Jiang, Meng-chuan Wang, Yang-ling Li. Targeted Therapy–Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap. Drug Design, Development and Therapy 2026; : 1 doi: 10.2147/DDDT.S600434
|
| 4 |
Hejing Bao, Caijiu Deng, Xi Luo, Haoran Su, Hehong Bao, Jiazhu Hu, Xiaolong Cao, Liping Lin. Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1785616
|